Clinical trial · Interventional
Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia
Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia: Cross-sectional Study
NCT07354191CI-TRIAL-00101353completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| direct antiglobulin test (DAT) | Diagnostic Test | — | UNRESOLVED |
| Indirect antiglobulin test (IAT) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MM patients
- description
- the prevalence of AIHA in MM patients and determine its impact on clinical presentation and outcome of the disease
- interventionNames
- Diagnostic Test: direct antiglobulin test (DAT)
- Diagnostic Test: Indirect antiglobulin test (IAT)
Primary outcomes (3)
- measure
- Measure prevalence of AIHA in MM patients .
- timeFrame
- baseline
- description
- Number of MM patients with AIHA
- measure
- Detect impact on International Prognostic Scoring System
- timeFrame
- baseline
- description
- relation of the presence of AIHA to the scoring system of the patient
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of multiple myeloma Exclusion Criteria: * No
References
Publications (4)
- BACKGROUNDBarcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J Clin Med. 2020 Nov 27;9(12):3859. doi: 10.3390/jcm9123859. PMID 33261023
- BACKGROUNDKashyap R, Singh A, Kumar P. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Asia Pac J Clin Oncol. 2016 Jun;12(2):e319-22. doi: 10.1111/ajco.12230. Epub 2014 Sep 22. PMID 25244430
- BACKGROUNDPacca RL, Silva JBCBD, Souza KCE, Carbinatto RB. Autoimmune hemolytic anemia and hyperglobulinemia leading to the diagnosis of multiple myeloma. Rev Bras Hematol Hemoter. 2017 Oct-Dec;39(4):357-359. doi: 10.1016/j.bjhh.2017.07.005. Epub 2017 Sep 4. No abstract available. PMID 29150110
- BACKGROUNDBird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J; Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011 Jul;154(1):32-75. doi: 10.1111/j.1365-2141.2011.08573.x. Epub 2011 May 14. No abstract available. PMID 21569004